Internship
Develops RNAi-based therapies for diseases
$22/hr
Madison, WI, USA + 2 more
More locations: Pasadena, CA, USA | San Diego, CA, USA
Upload your resume to see how it matches 6 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Arrowhead Pharmaceuticals develops medicines that treat severe diseases by targeting and silencing the genes responsible for them using RNA interference (RNAi). This process reduces the expression of specific genes, allowing for effective treatment of conditions like cystic fibrosis and hepatitis B. Unlike its competitors, Arrowhead focuses specifically on RNAi-based therapies, addressing unmet medical needs for diseases with limited treatment options. The company's goal is to provide new therapies that improve patient outcomes and advance the field of gene silencing.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Pasadena, California
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.
New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides
Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.
Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.
Arrowhead Pharmaceuticals unveiled a new RNAi-based obesity program on Wednesday that it believes could be "gentler" than currently available GLP-1 products...